NCT03206034

Brief Summary

Impairments in higher level cognitive processing, such as new learning and memory, are common in Multiple Sclerosis (MS) and negatively impact multiple aspects of everyday life, including occupational and social functioning. Despite this, few studies have attempted to remediate these cognitive deficits in order to improve everyday functioning. While not applied in traditional rehabilitation protocols as of yet, many techniques from cognitive psychology significantly improve learning and memory in healthy persons. These techniques include the generation effect (GE), the spacing effect (SE), and the testing effect (TE). These techniques have recently been incorporated into an 8-session treatment protocol, Stylistic Memory Enhancement (SME), designed to teach participants about each of the techniques, train them on how to apply the techniques in daily life and practice their application to daily life memory demanding situations. The protocol includes teaching participants how to restructure a memory demanding situation in order to make optimal use of self-generation, spaced learning and self-testing. The objective of the study is to test the efficacy of the SME in an MS population.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable multiple-sclerosis

Timeline
Completed

Started Mar 2013

Typical duration for not_applicable multiple-sclerosis

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2013

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2015

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

June 27, 2017

Completed
5 days until next milestone

First Posted

Study publicly available on registry

July 2, 2017

Completed
Last Updated

July 2, 2017

Status Verified

June 1, 2017

Enrollment Period

2.8 years

First QC Date

June 27, 2017

Last Update Submit

June 29, 2017

Conditions

Keywords

MemoryCognition

Outcome Measures

Primary Outcomes (1)

  • California Verbal Learning Test (CVLT-II- Total learning

    Measure of change in new learning

    Baseline and post-intervention (5 weeks between testing sessions)

Secondary Outcomes (1)

  • Memory Functioning Questionnaire

    Baseline and post-intervention ( 5 weeks between testing sessions)

Study Arms (2)

Treatment

EXPERIMENTAL

The experimental group will meet with a study team member twice a week for 4 weeks (8 sessions) and receive memory strategy training.

Behavioral: Stylistic Memory Enhancement

Control

PLACEBO COMPARATOR

The control group participants will meet with a study team member twice a week for 4 weeks (8 sessions) and receive control memory exercises.

Behavioral: Stylistic Memory Enhancement

Interventions

ControlTreatment

Eligibility Criteria

Age18 Years - 59 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Clinically definite MS between the ages of 18 and 59. Participants must have impairment in new learning (determined by an in-person screen) with intact language comprehension.

You may not qualify if:

  • History of alcohol or drug abuse/dependence,
  • Major psychiatric disturbance (e.g. bipolar disorder, schizophrenia) and neurological history other than MS.
  • Corticosteroid use within the last month prior to the participation.
  • Less than 1 month post most recent exacerbation.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Multiple Sclerosis

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNSAutoimmune Diseases of the Nervous SystemNervous System DiseasesDemyelinating DiseasesAutoimmune DiseasesImmune System Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Double blind placebo controlled randomized control trial
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director Neuropsychology and Neuroscience Research

Study Record Dates

First Submitted

June 27, 2017

First Posted

July 2, 2017

Study Start

March 1, 2013

Primary Completion

December 31, 2015

Study Completion

December 31, 2015

Last Updated

July 2, 2017

Record last verified: 2017-06

Data Sharing

IPD Sharing
Will not share